Development and testing of Streptococcus pneumoniae conjugate vaccines  by Klein, David L. & Eskola, Juhani
Development and testing of Streptococcus pneumoniae conjugate vaccines 
Clin Microbiol Itlfect 1999; 5 :  4S17-4S38 
David L. Kleiii * and]i-lhani Eskola' 
'National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA; 
'National Public Health Institute, Helsinlu, Finland 
INTRODUCTION 
Pneumococci are the largest cause of death resulting 
from infectious disease in the elderly, and cause the 
majority of ear infections in young children [1,2]. This 
organism is also an important cause of meningitis in 
young children and the elderly [3-51. Although ear 
infections in young children generally do not lead to 
meningitis or other serious pneumococcal diseases, 
they do result in costly clinic visits for the children and 
much lost work by their parents [6]. Because of its 
ability to infect the very young, the very old, and the 
immunodeficient, the pneumococcus has one of the 
largest public-health and economic impacts of any 
infectious disease. Globally, the pneumococcus remains 
a leading bacterial pathogen in adults and the fore- 
most cause of morbidity and mortality ir? infants and 
children in developing countries. Patients recovering 
from viral infections such as measles or influenza and 
those already afflicted with chronic diseases such as 
HIV constitute especially susceptible hosts in whom 
morbidity from the co-infecting pneumococcus is 
high. Overall, pneumococcal disease is a universal 
problem and has demanded an even greater amount of 
attention in recent years due to the advent of drug- 
resistant organisms. 
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Pneumococcal strains with resistance to many anti- 
biotics now exist, and indiscriminate use by physicians 
and healthcare providers has contributed to their wide- 
spread occurrence. This frequently introduces elements 
of uncertainty into formerly satisfactory treatment 
practices, particularly in the case of highly resistant 
strains [7,8]. Laboratory confirmation of antibiotic 
susceptibility patterns may take several days to com- 
plete, and clinicians are often forced to initiate 
treatment with broad-spectrum antibiotics such as 
cephalosporins and quinolones, a situation that may 
only accelerate antimicrobial resistance [9,10]. 
Therefore, preventing these infections with safe and 
effective vaccines will not only slow down the develop- 
ment of antibiotic resistance, but is a cost-effective way 
to control pneumococcal disease. The present conven- 
tional vaccine contains a mixture of 23 different 
polysaccharides [l 11. This vaccine is not immunogenic 
in young children, because of their inability to mount 
an adequate immune response to polysaccharide 
antigens. Additional data in groups that are considered 
to be at  high risk for life-threatening pneumococcal 
infections, such as the elderly, the immunocom- 
promised, the splenectoinized, those with sickle cell 
disease, and HIV-positive patients, have also shown 
only moderate to little efficacy after immunization 
with the conventional pneumococcal vaccine [13,13]. 
Among the elderly population, vaccine efficacy of the 
licensed pneumococcal vaccine is estimated to be 
approximately 60%, but goes down appreciably with 
increasing age. 
Much work has been done in developing pneumo- 
coccal conjugate vaccines as the next generation of 
promising vaccines against pneumococcal diseases. 
As with most T-independent antigens, the capsular 
pneumococcal polysaccharide vaccine induces an 
immune response that is short-lived and characterized 
by variable amounts of antibody that is dispro- 
portionately IgM [14]. It also fails to produce high 
antibody affinity and a booster response upon repeated 
immunization. Because of these problems, attention has 
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been given to the development of pneumococcal 
vaccines that more closely mimic protein vaccines 
currently used in infants and other high-risk popu- 
lations. One approach that has been used to immunize 
infants against infections from encapsulated bacteria 
(e.g. Haemopldus inzuenzae type b vaccine) is to present 
the capsular polysaccharide antigens in a form 
that is more immunogenic, such as in a protein- 
polysaccharide conjugate vaccine [I 51. The coupling of 
polysaccharides to protein carriers such as diphtheria 
and tetanus toxoids demonstrates that these polysac- 
charides can acquire new antigenic properties typical of 
‘T-dependent’ protein antigens [16,17]. They can 
stimulate a T-cell response, as shown in experimental 
animals, by their ability to use T-cell help to generate 
stronger ‘booster’ responses on re-stimulation [IS]. The 
goal of a pneumococcal conjugate vaccine is, therefore, 
to convert the normally T-independent saccharide into 
a T-dependent antigen that will be immunogenic and 
efficacious in non-responsive populations [ 191. 
The introduction of pneumococcal conjugate 
vaccines into the US vaccine armamentarium will 
address many of the major concerns about changing 
patterns of pneumococcal infection. It is anticipated 
that these new second-generation vaccines will help: 
(1) offset drug resistance and reduce antibiotic usage; 
(2) protect against the spread of uncontrolled invasive 
strains of pneumococci; (3) reduce the incidence of 
pneumococcal otitis media and tympanostomy; (4) 
reduce carriage and household/community transmission 
of pneumococci; and (5 )  promote a significant degree 
of herd immunity. A more effective vaccine for 
pneumococcal infection, therefore, represents a major 
public-health priority. 
Four major companies are involved in the develop- 
ment and manufacture of pneumococcal conjugate 
vaccines. The products vary slightly in their chemical 
composition and construct (e.g. different carrier 
proteins), and each of the products is in a different stage 
of clinical development (Table 1). There is a select 
group of important serotypes that is now included in 
all conjugate pneumococcal vaccines, because of their 
relative importance in the pathogenicity of the disease. 
The seven-valent vaccines contain serotypes 4, 6B, 9V, 
14, 18C, 19F and 23F, while the nine-valent vaccines 
add serotypes 1 and 5 and the 11-valent vaccines add 
serotypes 3 and 7E The protein carriers used to date 
are all functional entities and include tetanus toxoid, 
diphtheria toxoid, CRM 197 (a mutant protein of 
diphtheria toxoid), meningococcal outer-membrane 
complex, and non-typable H. injuenxae outer- 
membrane protein (Table 1). 
Widespread vaccination against a select group of 
common and important serotypes of Streptococcus 
pneumoniae could reduce infant mortahty and protect 
against antibiotic resistance by inducing titers of 
mucosal antibodies sufficient to eliminate naso- 
pharyngeal carriage. Based on the use of a seven-valent 
vaccine, a highly efficacious vaccine would have the 
potential to prevent up to 85% of invasive pneumo- 
coccal disease and 65% of pneumococcal otitis media 
in US children [20]. Little general clinical value will 
accrue for US children from the addition of serotypes 
1, 3, 5 and 7F to a seven-valent conjugate vaccine. The 
nine- and 11-valent vaccines were designed to benefit 
individuals in countries outside the USA as well as 
special high-risk groups (e.g. Inuits and American 
Indians). 
In the development of pneumococcal conjugates, 
the number of vaccine serotypes included in the 
construct is limited because of the need to conjugate 
each serotype as an individual entity. For now, the 11- 
valent vaccine appears to be the industry standard, 
although there has been some discussion on whether 
an additional two serotypes should be added to the mix. 
The FDA would probably favor a uniform approach 
among the different vaccine manufacturers with regard 
to the number of valences that are included in each of 
the multivalent pneumococcal conjugate vaccines, to 
avoid confusion within the medical community. 
CLINICAL DATA THAT HAVE CONTRIBUTED TO THE 
CHARACTERIZATION OF CONJUGATE VACCINES 
Some of the earliest and most significant clinical studies 
to date have been conducted in Finland. Table 2 
shows the results of four separate clinical trials, all done 
in a common setting using four different conjugate 
pneumococcal vaccines administered at 2, 4 and 6 
months of age [21]. Each trial used a similar protocol 
and incorporated common laboratory procedures that 
included a standardized ELISA assay. AU four vaccines 
were considered safe, with no indications of any serious 
adverse events. All four vaccines also induced signi- 
ficant levels of antibody to each of the serotypes tested 
after three immunizations at 2 ,  4 and 6 months. Some 
serotypes were more immunogenic than others (e.g. 14 
and 19F), while serotypes 6B and 23F were con- 
siderably less immunogenic. This appears to be the 
trend for all the pneumococcal conjugate vaccines, 
regardless of manufacturer. Unfortunately, it is not 
possible to make any true comparisons here, since the 
studies were not done head-to-head and the vaccines 
were not optimal end-stage formulas, but early 
prototype vaccines. 
Another study demonstrated the ability to boost a 
primary response among infants immunized with a 
four-valent conjugate vaccine at 2, 4 and 6 months of 
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Table 2 Immune response in infants to four different 
quadrivalent pneumococcal conjugate vaccines administered 
at 2, 4 and 6 months of age: antibody concentration (mg/L) 
at 7 months of age 
Vaccine 6B 14 19F 23F 
PncCRM 0.40 2.50 0.79 1.10 
PncOMP 1.30 8.27 9.85 1.90 
PnCD 0.88 2.30 5.29 0.88 
PncT 0.77 3.06 3.20 0.67 
~~ 
PncCRM, WyethILederle; PncOMP, Merck Research 
Laboratones; PnCD, PasteudMeriewdConnaught; 
PncT, Pasteur/Merieux/Connaught. 
age (Table 3) [22]. One group of children was primed 
and boosted with a conjugate vaccine at 14 months, 
while a second group was primed with conjugate 
vaccine, but boosted with plain polysaccharide, again at 
14 months. The data indicate that antibody levels 
declined significantly (2-4-fold) by 14 months follow- 
ing the initial priming immunization. However, 1 
month after a booster dose of vaccine, there was a 
6-10-fold increase in antibody activity for each of the 
vaccine serotypes in both study groups. Furthermore, 
>90% of children in both groups had antibody 
concentrations > 1 .O mg/L for all serotypes measured. 
The results indicate that pneumococcal conjugate 
vaccines confer properties of T-dependent antigens to 
polysac-charides and elicit immunologic memory and 
that it is possible to boost with a polysaccharide vaccine 
after priming infants first with a conjugate vaccine. 
The capacity of pneumococcal conjugate vaccines 
to prime for an anarnnestic response was also observed 
in a study conducted in The Gambia [23]. Children, 
who were all previously primed at infancy with either 
two or three doses of a five-valent pneumococcal 
conjugate vaccine or three doses of a control Hib 
conjugate vaccine, were boosted at 2 years of age with 
a 23-valent polysaccharide vaccine. The data reveal that 
three priming doses were better than two in producing 
consistently higher antibody levels (51 mg/L versus 28 
mg/L respectively) (Table 4). Antibody concentrations 
were measured 2 years post-priming, but immediately 
before the boost had dropped precipitously (pre-3 
levels). The rise in antibody concentrations 10 days 
following the polysaccharide boost was striking, 
regardless of whether two or three priming doses were 
used. It was surprising to see high antibody titers to 
serotype 6B in Gambian children, given its status as a 
weak immunogen. Again, these results reinforce the 
idea that pneumococcal conjugate vaccines are capable 
of priming the immune system to respond to sub- 
sequent exposures to capsular polysaccharide antigens 
associated with the pneumococcal organism. 
Several studies have been done in healthy adults 
and the elderly to determine the impact of pneumo- 
coccal conjugate vaccines in these populations [24-271. 
In one such study, healthy adults received either one of 
four conjugate vaccines or a 23-valent polysaccharide 
vaccine (Figure 1) [27]. The results are expressed as a 
ratio of conjugate vaccine/polysaccharide vaccine geo- 
metric mean concentrations (GMC), with ratios B1.0 
indicative of a better response for the conjugate vaccine 
and ratios < 1 .O indicative of a better response for the 
polysaccharide vaccine. In general, the levels of IgG 
antibodies to serotypes 6B and 23F were greater 
following immunization with a conjugate vaccine (with 
one exception), and the levels of antibodies to serotype 
14 were greater following immunization with a poly- 
saccharide vaccine. This equivocal pattern of response 
has prompted additional studies in the elderly with 
newer versions of conjugate vaccines to determine 
whether other vaccine schedules may provide for a 
more favorable outcome. 
In addition to measuring antibody concentrations 
following vaccination, it is important to evaluate the 
qualitative characteristics of antibody production (i.e. 
avidity and opsonic antibody activity) that are im- 
portant in assessing the effectiveness of pneumococcal 
conjugate vaccines [28]. To address this issue, a study 
was conducted in which infants were primed with a 
tetravalent conjugate vaccine at 2, 4 and 6 months of 
Table 3 Infants primed with a four-valent pneumococcal conjugate vaccine at 2, 4 and 6 months and boosted at 14 
months: GMC mg/L in infants at various months of age 
Vaccine PS 6B PS 23F 
Study group Primary Booster n 7 14 15 7 14 15 
1 
2 
PncD PncD 36 0.81 0.39 2.62 0.75 0.21 1.17 
PncD PncPS 35 1.45 0.49 3.03 0.71 0.29 2.79 
PncD, conjugate of PSs of serotypes 6B, 14, 19F and 23F to diphtheria toxoid; PncPS, 23-valent pneumococcal PS vaccine; 
GMC, geometric mean concentration; PS, polysaccharide. 
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Table 4 Antibody concentrations after a PncPS boost at 
two years of age in Gambian infants primed with either 
three doses of a Hib conjugate vaccine or with two or three 
doses of a five-valent pneumococcal conjugate vaccine 123) 
Antibody concentration (mg/L) 
None Pre-3 Post-2 Post-3 
6B 0.37 0.89 27.62 50.90 
14 0.73 1.98 15.28 30.52 
18C 1.62 0.30 5.82 7.26 
19 0.57 0.99 5.70 10.33 
23F 0.28 0.63 4.17 6.64 
None=immunized 17 months previously with a Hib conjugate 
vaccine. 
Pre-3=antibody levels 2 years aher priming. 
Post-Z=received two doses of conjugate vaccine at 2 and 4 
months. 
Post-3=received three doses of conjugate vaccine at 2, 3 and 4 
months. 
PncPS = pneumococcal polysaccharide. 
age and boosted at 14 months with either the same 
conjugate vaccine or a 23-valent polysaccharide 
vaccine [29]. An increase in the avidity of antibody 
binding to the vaccine serotypes was observed only 
among children boosted with the conjugate vaccine, 
but not among the recipients of plain polysaccharide 
(Figure 2). Avidity was also shown to correlate with 
fbnctional opsonic antibody activity. These results may 
have significant cost implications with regard to vaccine 
strategies. Although data indicate that boosting with a 
plain polysaccharide vaccine produces a significant 
increase in antibody activity against each of the 
serotypes contained in the priming vaccine, the 
functional activity of these antibodies compared to 
antibodies following a boost with a conjugate vaccine 
may be inferior and, therefore, provide for a lesser 
degree of protection. It is also possible that boosting 
with a conjugate vaccine may improve the duration of 
the protective antibody response [30]. 
There was concern over whether children less than 
2 years of age with recurrent respiratory infections, 
who failed to respond to polysaccharide vaccine, would 
be able to respond to a pneumococcal conjugate 
vaccine. It is estimated that between 5% and 10% of 
children with recurrent respiratory infections are 
unresponsive to the conventional polysaccharide vac- 
cine [31]. To examine the effectiveness of a conjugate 
vaccine in this population, children 2-13 years of age 
with no  known immunodeficiencies were recruited 
into the study (Figure 3). All the children received a 
pneumococcal polysaccharide vaccine followed six 
months later by either a heptavalent conjugate vaccine 
or plain pneumococcal polysaccharide [32]. The results 
indicate that poor responders to the polysaccharide 
vaccine are able to respond significantly better, overall, 
to a single dose of conjugate vaccine, with increased 
antibody concentrations in response to all serotypes 
tested. Immunization with conjugate vaccines may thus 
represent a viable option for patients at high risk for 
u) 
0 .- 
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P 
66 14 23F 
PncCRM 
II PncCRM 
PncOMPC 
PncD 
Figure 1 Ratio of GMCs (conjugate/PS) after pneumococcal vaccination in healthy adults: C/P, conjugate 
vaccine/polysaccharide vaccine ratio; GMC, geometric mean concentration; PS, polysaccharide; PncCRM, five-component 
pneumococcal oligosaccharide conjugate with CRM 197 protein carrier (Wyeth Lederle); PncOMPC, pneumococcal 
conjugate with outer-membrane protein complex carrier (Merck Research Laboratories); PnCD, pneumococcal conjugate 
with diphtheria carrier (Pasteur/Merieux/Connaught); PnCRM, seven-component pneumococcal conjugate with CRM 
197 protein carrier (Wyeth-Lederle) [24,27]. 
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Figure 2 Increase in avidity of antibodies after booster vaccination: PncD, PMC pneumococcal conjugate vaccine; PncPS, 
23-valent pneumococcal polysaccharide vaccine [29]. 
recurrent respiratory infections who fail to respond 
initially to the currently available 23-valent poly- 
saccharide vaccine. 
Pneumococcal conjugate vaccines have also demon- 
strated tremendous value in other high-risk groups, 
including Hodgkin’s disease patients [33], and HIV- 
infected children [34]. In general, a significant increase 
was observed in the number of responders with 
antibody levels greater than 1.0 mg/L following one or 
more doses of conjugate vaccine. These results further 
suggest that priming with conjugate vaccines may 
represent a good strategy for high-risk populations. 
An important consideration when administering 
pneumococcal conjugate vaccines to children is the 
potential impact they may have on colonization and 
transmission of the organism. A good example of the 
effect that a multivalent pneumococcal conjugate 
vaccine has on nasopharyngeal carriage was observed 
in Israeli toddlers. Day-care children received either a 
single dose of a nine-valent conjugate vaccine or a 
conjugate meningococcal C vaccine [35]. Figure 4 
shows the nasopharyngeal carriage results 8 months 
Eollowing vaccination. Carriage rates were reduced 
for all vaccine serotypes as well as for penicillin- 
resistant, multi-resistant and non-resistant vaccine 
types, especially in children less thx: 34 months of age 
a t  the time of vaccination. These data indicate that 
conjugate vaccines are capable of reducing the coloni- 
zation of vaccine-related serotypes significantly, as well 
as decreasing the burden of antibiotic-resistant strains. 
Similar stumes were conducted in Gambian and 
South African infant populations [36,37]. Again, a 
reduction was observed in the pharyngeal carriage rates 
of serotypes associated with the 7-valent pneumococcal 
conjugate vaccine following its vaccination into infants 
(Figure 5). Interestingly, the figure also shows an 
increase in non-vaccine serotypes among infants in 
both locations who received the pneumococcal con- 
jugate vaccine compared to a placebo (i.e. conjugate 
meningococcal C vaccine). This latter data suggest that 
replacement and/or unmasking of pneumococcal sero- 
types occurs in the host following immunization with 
a pneumococcal conjugate vaccine due to successful 
competition by non-vaccine serotypes. Whether this is 
truly a replacement phenomenon (i.e. new serotypes 
occupying available niches) or the unmasking of 
serotypes present previously, but not expressed due to 
the prevalence of more dominant types, or both, is 
unclear at this time. The real question and concern 
is whether replacement carriage will translate into 
replacement pneumococcal disease. 
RECENT VACCINE TRIALS THAT DEFINE EFFICACY 
Currently, there are four efficacy trials in progress 
evaluating three different pneumococcal multivalent 
conjugate vaccines manufactured by two companies 
(Wyeth-Lederle Vaccines and Pediatrics and Merck 
Research Laboratories) (Table 5). The endpoints for 
these four trials vary considerably from acute otitis 
media to invasive disease. Recently, a large-scale phase 
111 clinical trial involving approximately 38 000 infants 
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Figure 3 Response to 23-valent pneumococcal polysaccharide vaccine (PncPS) or Wyeth-Lederle pneumococcal conjugate 
vaccine (PncCRM) in children with recurrent infections [32]. 
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Figure 4 Pneumococcal carriage after PncCRM in Israeli toddlers: PncCRM, Wyeth-Lederle pneumococcal conjugate 
vaccine; Pnc, pneumococci; VT Pnc, vaccine-type pneumococci; Pen-R, penicillin-resistant types; MDR, niultiresistant; 
Control, meningococcal C conjugate vaccine [35]. 
4 6 2 4  C l in ica l  M i c r o b i o l o g y  a n d  In fec t ion ,  V o l u m e  5 S u p p l e m e n t  4 
Table 5 Ongoing and planned eficacy trials with pneumococcal conjugate vaccines 
Site Vaccine Starting year Endpoint 
~~ ~ 
USA (recently completed) PncCRM, 7-valent 1995 Invasive dlsease 
Finland PncCRM, 7-valent 1995 0 0 0 s  medla 
USA (Navajo/Apache infants) PncCRM, 7-valent 1998 Invasive &sease/herd immunity 
South Afiica PncCRM, 9-valent 1998 Invasive &sease 
Gambia (phase I1 ongoing) PncCRM, 9-valent 1999 Mortality/morbidlty 
Israel PncD+T, 11-valent 1999 OhOS media 
Phhppines PncD+T, 11-valent 1999 Invasive dlsease 
Clule PncD+T, 11-dent  2000 Invasive dlsease 
PnCRM, Wyeth-Lederle, PncOMPC, Merck Reseuch Laboratories, PncD+T, Pasteur/Merieux/Connaught 
PncOMPC, 7-valent 
Table 6 Breakdown of cases reported in the Northern California Kaiser Permanente Efficacy Trial 
Number of cases 
Group Vaccine group Control group Serotypes 
Fully vaccinated 0 
Partially vaccinated 0 
Non-vaccine serotype 3 b  
17 
5" 
5 
6B, 9V, 14, 18C 19E 23F 
6B, 14, 19E 23F 
3, lOF, 11A, 18B, 19A, 23A, 38 
"Three with one dose, two with two doses. 
b T ~ o  fully vaccinated and one partially vaccinated. 
was unblinded and the results published [38]. The trial 
involved the use of a Wyeth-Lederle pneumococcal 
conjugate vaccine and was conducted at a Northern 
California Kaiser Permanente Health Maintenance 
Organization (HMO). The infants were randomized to 
receive either a pneumococcal conjugate vaccine or a 
meningococcal C conjugate vaccine, both produced by 
Wyeth-Lederle. The pneumococcal conjugate vaccine 
was formulated to protect against the seven most 
The Gambia 
common strains of S. pneumoniae in the USA 
(polysaccharide serotypes 4, 6B, 9V, 14, 19F and 23F, 
and oligosaccharide serotype 18C) and included 20 pg 
of the carrier CRM197, a mutant form of diphtheria 
toxin. The infants were vaccinated at 2, 4, and 6 
months of age, in addition to a conjugate booster at 
12-15 months of age, and followed for disease. The 
trial was designed to have an initial look at the efficacy 
data once 17 fully vaccinated cases of invasive disease 
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Figure 5 Reduction of pharyngeal carriage after PncCRM vaccination in infancy: PncCRM, Wyeth-Lederle pneumo- 
coccal conjugate vaccine; Placebo, meningococcal C conjugate vaccine; VT, vaccine types; Others, non-vaccine serotypes 
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were documented. The results outlined in Table 6 are 
very encouraging and reveal 100% efficacy (95% CI = 
75.7-100.0, p<0.0001) for the conjugate pneumo- 
coccal vaccine against invasive disease following either 
full vaccination or partial vaccination. Unfortunately, 
none of the cases in the vaccinated control group 
included meningitis, and none of the children in the 
study was considered to be at high risk. 
A randomized, double-blind safety and immuno- 
genicity study was run concurrently with the efficacy 
study. The trial enrolled 212 healthy 2-month-old 
infants at four clinical sites. The infants received 
identical vaccines to those used in the efficacy trial (i.e. 
half received the pneumococcal conjugate vaccine and 
the other half the meningococcal C conjugate vaccine). 
Each child was given doses of vaccine at 2, 4 and 
6 months, and those who remained in the study 
received a booster at 12-15 months. Results showed 
that the conjugate vaccine was highly immunogenic, 
produced a good antibody response against all seven 
strains of S. pneurnoniae, was well tolerated, with only 
minor reactions at the injection site, and caused only 
mild-to-moderate post-vaccination fever in some 
children [39]. 
During the next 12-18 months, several additional 
efficacy trials are expected to begin at  four sites outside 
the USA (i.e. Israel, The Gambia, the Philippines, and 
Chile) (Table 5). Many important issues will be 
addressed in addition to the question of vaccine safety 
and the effect that these conjugate vaccines have on 
protective efficacy. These include: (I) determining 
laboratory correlates of protection; (2) examining 
interference with other childhood vaccines; and (3) 
evaluating the overall impact on ecology (i.e. herd 
immunity) and colonization. Many of the conjugate 
vaccines in these new trials will contain as many as 11 
serotypes. In the near future, other phase I1 and phase 
I11 studies may be needed in special populations to 
adequately describe the ability of pneumococcal 
conjugate vaccines to serve as good immunogens as 
well as protect against disease. These populations will 
include several high-risk groups, such as sickle cell 
patients, the elderly, pregnant women in their third 
trimester, immunocompromised patients, and pre- 
mature infants oflow birth weight. The main objectives 
will be to determine whether conjugate vaccines offer 
any significant advantage over conventional 23-valent 
capsular polysaccharide vaccines with regard to safety 
and iinmunogenicity. Many of the existing data suggest 
that the pneumococcal conjugate vaccines will have 
their greatest impact in populations (e.g. infants and 
high-risk groups) that do not respond well to the 23- 
valent polysaccharide vaccine when used as a primary 
inoculum [40]. 
ALTERNATIVE PNEUMOCOCCAL VACCINE STRATEGIES 
The use of polysaccharide-protein conjugate vaccines, 
while overcoming many of the liabilities of poly- 
saccharide vaccines, still involves a number of problems. 
First, new studies indicate that immunity induced by 
pneumococcal conjugate vaccines may be short-lived, 
especially in infants. Such a limitation would necessitate 
repeat vaccinations through the first several years of 
life-an expensive procedure even in relatively wealthy 
nations, but an even greater and prohibitive expense for 
the developing world, where cost factors play a major 
role in deciding whether or not a vaccine gets used. 
Second, regional variations in the predominance of 
infecting pneumococcal serotypes necessitate the 
formulation of capsule-based vaccines that are appro- 
priate to the local epidemiology. Such modifications are 
not only technologically difficult, but also exceedingly 
expensive. Third, because serotype coverage is severely 
restricted by the inclusion of only 11 serotypes, the 
capacity to promote wide protection against infections 
in developing countries is limited. At best, an 1 I-valent 
conjugate vaccine would cover only three-quarters of 
serotypes causing disease that may vary over time. 
Fourth, because the multivalent vaccines are made up 
of individual vaccines, a large total dose of carrier 
protein is required that may subsequently lead to 
carrier-induced suppression/overload, or even anti- 
carrier proteins [41, 421. Last, the ability of pneumo- 
cocci to change their capsular serotype as a result of 
uptake of heterologous DNA suggests that the pro- 
tective effect of anti-capsular antibody may be all too 
temporary, as vaccine serotypes ‘deliberately’ modify 
their surface polysaccharide in response to niucosal 
antibodies and other seiective pressures [43]. 
All of these considerations lead to the conclusion 
that new generations of pneumococcal vaccines will be 
needed to address many of these problems. Just as 
capsular polysaccharide vaccines have now given way 
to protein-polysaccharide conjugates, future pneumo- 
coccal surface proteins, which represent excellent 
virulence determinants that are immunogenic and con- 
served among global serotypes, will lead the way as 
third-generation vaccines. These new surface protein 
vaccines most probably will be employed either as the 
carrier component in conjugate vaccines or as an 
individual vaccine combined with an adjuvant or 
cytokine [44-491. The use of such proteins as im- 
munizing antigens might serve not only to prevent 
colonization in fully immunized hosts, but also to 
ameliorate the effects of breakthrough infections in 
incompletely protected populations such as infants. 
Work in international laboratories has shown that 
several different pneumococcal surface proteins such as 
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Table 7 Questions remaining after current efficacy trials 
Persistence of antibodies and protection 
Impact on the epidemiology of pneumococcal infections 
Potential indications in other target groups, such as premature 
infants, pregnant women, elderly individuals, 
immunocompromised individuals, including HIV-positive 
infants, nephrotics, splenectomized subjects and bone marrow 
transplant recipients 
Schedule, combinations, immunization route 
Possible interference with other childhood vaccines 
Cost-effectiveness analysis 
Benefit of adding adjuvants to improve immune response 
Need for additional serotypes and improved formulations 
Standardization of laboratory methodology for total and 
Optimal use of the vaccine with regard to: 
functional antibody 
Role of cell-mediated immunity in protection 
Search for surrogates of  protection 
Role of genetic transformation on conjugate vaccine effectiveness 
Table 8 Problems associated with pneumococcal conjugate 
vaccines 
~ ~~ 
Cost of producing vaccine and limited potential in developing 
Need for multivalent products made up of individual vaccines 
Need for mfferent formulations, dosages and combinations of 
serotypes to accommodate different populations, age groups 
and geographic needs 
Problem with carrier-induced suppression, or overload due to large 
total dose o f  carrier protein 
Currently, vaccine covers, at best, only three-quarters of types 
causing disease that may vary over time 
The majority of pneumococcal morbidity is associated with 
mucosal infections that conjugate vaccines do not addess 
Each conjugated antigen is a unique, separate vaccine with different 
immunologic properties-makes for a very complex product 
countries 
pneumococcal surface protein A (PspA) [45,49], pneu- 
mococcal surface adhesin A (PsaA) [46], neuraminidase 
[44] and autolysin [48] are able to elicit active 
protection against pneumococcal infection in mice 
when challenged with lethal doses of pneumococci. 
More recent data strongly indicate that antibody to 
PspA in human serum can protect mice from fatal 
pneumococcal infection [50]. As a result of these 
studies, PspA is now being developed as a human 
vaccine by a major vaccine manufacturer, and is now in 
phase I trials. Because of the conserved nature of these 
surface proteins, it is possible that they will provide a 
broader vaccine application and greater overall 
protection against serotypes causing pneumococcal 
disease than do conjugate vaccines. In addition, surface 
protein vaccines may have the ability to stimulate a 
protective respiratory tract mucosal immune response 
when administered parenterally, something not observed 
generally with conjugate vaccines [51]. 
SUMMARY 
Even after the completion of the phase 111 trials and the 
possible licensing of pneumococcal conjugate vaccines, 
numerous outstanding issues and questions, both basic 
and clinical, remain to be addressed, as outlined in 
Tables 7 and 8. 
Pneumococcal conjugate vaccines have evolved 
considerably over the past several years and appear to 
offer a number of opportunities for various high-risk 
groups compared to the licensed polysaccharide 
vaccines. What we know and can say about pneumo- 
coccal conjugate vaccines at this time is summarized 
below: 
All pneumococcal conjugate vaccines are not created 
equally. Furthermore, each conjugated antigen is a 
unique, separate vaccine with different immunologic 
properties. 
Conjugate vaccines produce increased immunologic 
responses compared to the plain polysaccharide 
vaccine. 
All pneumococcal conjugate vaccines have been 
found to be relatively safe and well tolerated, with no 
reported serious adverse events. 
Repeated injections following a priming immuni- 
zation with conjugate vaccine elicits both IgG and 
hnctional antibody. 
Conjugate vaccines appear to work best in infants 
and high-risk groups. 
Conjugate vaccines induce immunologic memory. 
Immunogenicity has been shown to vary significantly 
among serotypes in terms of magnitude and kinetics 
of response. 
Conjugate vaccines can decrease nasopharyngeal 
carriage rates and, thus, reduce the transmission of 
pneumococci in community and specialized settings. 
There are no antibody data that show what antibody 
concentrations are needed for protection. 
Pneumococcal conjugate vaccines may protect 
against the spread of uncontrolled invasive strains. 
The routine use of pneumococcal conjugate vaccines 
may represent the most successful approach to 
decreasing the burden of antibiotic-resistant strains of 
pneumococci. 
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